project . 2020 - 2022 . On going

ATAC

Antibody therapy against coronavirus (COVID-19)
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 101003650 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
  • Funded under: H2020 | RIA Overall Budget: 3,020,040 EURFunder Contribution: 2,995,040 EUR
  • Status: On going
  • Start Date
    01 Apr 2020
    End Date
    31 Mar 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
ATAC aims at developing passive immunotherapy against COVID-19. Human antibodies will be obtained from blood of CoV-recovered donors from China and Italy with three independent approaches: polyclonal gamma-globulins, B cell monoclonals and phage libraries. Antibodies will be characterized by rapid experimental and computational work, optimized, produced and tested in consultation with EMA to ensure prompt embedding of regulatory aspects. The partners have outstanding experience in all aspects of the project, collaborated previously and worked on antibody therapy for diseases including SARS and MERS-CoV. Reagents and experienced personnel are already available en...
Description
ATAC aims at developing passive immunotherapy against COVID-19. Human antibodies will be obtained from blood of CoV-recovered donors from China and Italy with three independent approaches: polyclonal gamma-globulins, B cell monoclonals and phage libraries. Antibodies will be characterized by rapid experimental and computational work, optimized, produced and tested in consultation with EMA to ensure prompt embedding of regulatory aspects. The partners have outstanding experience in all aspects of the project, collaborated previously and worked on antibody therapy for diseases including SARS and MERS-CoV. Reagents and experienced personnel are already available en...
Any information missing or wrong?Report an Issue